Spruce biosciences reports third quarter 2023 financial results and provides corporate updates

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended september 30, 2023 and provided corporate updates. “achieving completion of enrollment milestones in the cahptain-205 and cahmelia-203 studies underscores the strong execution of our key c.
SPRB Ratings Summary
SPRB Quant Ranking